$7.15 Billion is the total value of RA Capital Management's 82 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 48.6% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ASND | Sell | ASCENDIS PHARMA A Ssponsored adr | $978,221,000 | +7.3% | 5,865,338 | -0.8% | 13.68% | -18.0% |
TGTX | Sell | TG THERAPEUTICS INC | $451,818,000 | +91.3% | 8,685,471 | -1.6% | 6.32% | +46.2% |
NVAX | Buy | NOVAVAX INC | $422,463,000 | +225.3% | 3,788,564 | +216.1% | 5.91% | +148.7% |
NKTX | NKARTA INC | $344,547,000 | +104.5% | 5,605,129 | 0.0% | 4.82% | +56.3% | |
FMTX | FORMA THERAPEUTICS HLDGS INC | $314,507,000 | -30.0% | 9,011,651 | 0.0% | 4.40% | -46.5% | |
ARVN | ARVINAS INC | $311,937,000 | +259.7% | 3,672,872 | 0.0% | 4.36% | +175.0% | |
CCXI | Sell | CHEMOCENTRYX INC | $295,764,000 | +11.8% | 4,776,548 | -1.0% | 4.13% | -14.6% |
AVIR | New | ATEA PHARMACEUTICALS INC | $224,294,000 | – | 5,368,451 | +100.0% | 3.14% | – |
ITOS | ITEOS THERAPEUTICS INC | $149,392,000 | +37.1% | 4,417,258 | 0.0% | 2.09% | +4.8% | |
KNTE | New | KINNATE BIOPHARMA INC | $142,932,000 | – | 3,593,052 | +100.0% | 2.00% | – |
AXSM | Sell | AXSOME THERAPEUTICS INC | $134,869,000 | -7.0% | 1,655,447 | -18.7% | 1.88% | -28.9% |
KROS | KEROS THERAPEUTICS INC | $132,263,000 | +82.9% | 1,875,000 | 0.0% | 1.85% | +39.8% | |
PHAT | PHATHOM PHARMACEUTICALS INC | $127,067,000 | -9.4% | 3,825,008 | 0.0% | 1.78% | -30.8% | |
RYTM | Sell | RHYTHM PHARMACEUTICALS INC | $124,244,000 | +11.5% | 4,179,067 | -18.7% | 1.74% | -14.7% |
TVTX | New | TRAVERE THERAPEUTICS INC | $124,225,000 | – | 4,557,867 | +100.0% | 1.74% | – |
IMGN | Buy | IMMUNOGEN INC | $118,793,000 | +368.7% | 18,417,458 | +161.6% | 1.66% | +258.0% |
RCKT | New | ROCKET PHARMACEUTICALS INC COM | $117,143,000 | – | 2,136,081 | +100.0% | 1.64% | – |
ETNB | 89BIO INC | $115,422,000 | -5.0% | 4,736,214 | 0.0% | 1.61% | -27.4% | |
ZGNX | Sell | ZOGENIX INC | $106,859,000 | +8.6% | 5,345,631 | -2.6% | 1.49% | -17.0% |
PMVP | PMV PHARMACEUTICALS INC | $105,198,000 | +73.3% | 1,710,265 | 0.0% | 1.47% | +32.4% | |
OLMA | New | OLEMA PHARMACEUTICALS INC | $103,391,000 | – | 2,150,404 | +100.0% | 1.44% | – |
ADVM | Buy | ADVERUM BIOTECHNOLOGIES INC | $103,006,000 | +6.3% | 9,502,383 | +1.0% | 1.44% | -18.8% |
MGNX | MACROGENICS INC | $100,017,000 | -9.3% | 4,375,217 | 0.0% | 1.40% | -30.7% | |
PCVX | Sell | VAXCYTE INC | $98,593,000 | -62.2% | 3,710,699 | -29.8% | 1.38% | -71.1% |
IGMS | IGM BIOSCIENCES INC | $86,765,000 | +19.6% | 982,723 | 0.0% | 1.21% | -8.6% | |
BDTX | BLACK DIAMOND THERAPEUTICS INC | $83,006,000 | +6.0% | 2,589,904 | 0.0% | 1.16% | -19.0% | |
SBTX | New | SILVERBACK THERAPEUTICS INC | $80,733,000 | – | 1,742,186 | +100.0% | 1.13% | – |
Sell | TRILLIUM THERAPEUTICS INC | $77,823,000 | -11.1% | 5,290,481 | -14.2% | 1.09% | -32.1% | |
SLDB | Buy | SOLID BIOSCIENCES INC | $75,622,000 | +715.0% | 9,976,569 | +118.3% | 1.06% | +521.8% |
KALA | KALA PHARMACEUTICALS INC | $73,730,000 | -9.6% | 10,874,613 | 0.0% | 1.03% | -30.9% | |
FPRX | New | FIVE PRIME THERAPEUTICS INC | $72,891,000 | – | 4,285,161 | +100.0% | 1.02% | – |
INBX | INHIBRX INC | $70,193,000 | +83.2% | 2,129,003 | 0.0% | 0.98% | +39.9% | |
LEGN | LEGEND BIOTECH CORPsponsored ads | $67,818,000 | -8.8% | 2,408,292 | 0.0% | 0.95% | -30.3% | |
CRIS | New | CURIS INC | $63,127,000 | – | 7,707,790 | +100.0% | 0.88% | – |
WVE | WAVE LIFE SCIENCES LTD | $61,191,000 | -7.3% | 7,775,207 | 0.0% | 0.86% | -29.2% | |
CRDF | CARDIFF ONCOLOGY INC | $59,187,000 | +26.8% | 3,290,000 | 0.0% | 0.83% | -3.2% | |
DYN | DYNE THERAPEUTICS INC | $58,906,000 | +4.0% | 2,805,045 | 0.0% | 0.82% | -20.6% | |
CNST | New | CONSTELLATION PHARMCETICLS INC | $53,359,000 | – | 1,852,746 | +100.0% | 0.75% | – |
PACB | New | PACIFIC BIOSCIENCES OF CALIFORNIA INC | $51,569,000 | – | 1,987,997 | +100.0% | 0.72% | – |
GERN | GERON CORP | $47,901,000 | -8.6% | 30,126,299 | 0.0% | 0.67% | -30.1% | |
STRO | SUTRO BIOPHARMA INC | $45,986,000 | +116.0% | 2,118,212 | 0.0% | 0.64% | +65.3% | |
CCCC | New | C4 THERAPEUTICS INC | $45,639,000 | – | 1,377,569 | +100.0% | 0.64% | – |
AKUS | AKOUOS INC | $45,237,000 | -13.3% | 2,281,249 | 0.0% | 0.63% | -33.8% | |
RLAY | RELAY THERAPEUTICS INC | $41,560,000 | -2.4% | 1,000,000 | 0.0% | 0.58% | -25.4% | |
INZY | INOZYME PHARMA INC | $41,355,000 | -21.5% | 2,003,653 | 0.0% | 0.58% | -40.0% | |
ORTX | ORCHARD THERAPEUTICS PLCads | $41,155,000 | -18.7% | 12,315,213 | 0.0% | 0.58% | -37.9% | |
ARDX | Sell | ARDELYX INC | $39,875,000 | +21.3% | 6,163,086 | -1.6% | 0.56% | -7.3% |
CERE | New | CEREVEL THERAPEUTICS HLDNG INC | $36,476,000 | – | 2,200,000 | +100.0% | 0.51% | – |
ARQT | ARCUTIS BIOTHERAPEUTICS INC | $32,777,000 | -4.0% | 1,165,184 | 0.0% | 0.46% | -26.6% | |
LRMR | LARIMAR THERAPEUTICS INC | $32,439,000 | +41.1% | 1,515,151 | 0.0% | 0.45% | +7.9% | |
VRNA | VERONA PHARMA PLCsponsored ads | $31,824,000 | 0.0% | 5,100,000 | 0.0% | 0.44% | -23.5% | |
PAND | PANDION THERAPEUTICS INC | $26,285,000 | +29.6% | 1,770,023 | 0.0% | 0.37% | -1.1% | |
ALEC | Sell | ALECTOR INC | $24,463,000 | -35.8% | 1,616,879 | -55.3% | 0.34% | -50.9% |
CNCE | Sell | CONCERT PHARMACEUTICALS INC | $23,049,000 | +26.3% | 1,823,520 | -1.9% | 0.32% | -3.6% |
SNDX | SYNDAX PHARMACEUTICALS INC | $22,753,000 | +50.7% | 1,023,067 | 0.0% | 0.32% | +15.2% | |
STSA | SATSUMA PHARMACEUTICALS INC | $21,583,000 | +18.5% | 4,681,858 | 0.0% | 0.30% | -9.3% | |
ORIC | New | ORIC PHARMACEUTICALS INC | $19,768,000 | – | 584,000 | +100.0% | 0.28% | – |
SCPH | SCPHARMACEUTICALS INC | $18,615,000 | -29.0% | 3,518,998 | 0.0% | 0.26% | -45.8% | |
New | MARINUS PHARMACEUTICALS INC | $15,860,000 | – | 1,300,000 | +100.0% | 0.22% | – | |
VXRT | Sell | VAXART INC | $15,658,000 | -78.2% | 2,742,271 | -74.6% | 0.22% | -83.3% |
MIST | Sell | MILESTONE PHARMACEUTICALS INC | $15,596,000 | -11.9% | 2,327,714 | -3.8% | 0.22% | -32.7% |
OCUL | Sell | OCULAR THERAPEUTIX INC | $15,525,000 | -25.2% | 750,000 | -72.5% | 0.22% | -42.9% |
BCTG | BCTG ACQUISITION CORP | $14,300,000 | +10.4% | 1,250,000 | 0.0% | 0.20% | -15.6% | |
RPTX | REPARE THERAPEUTICS INC | $14,029,000 | +11.5% | 409,000 | 0.0% | 0.20% | -14.8% | |
BLSA | New | BCLS ACQUISITION CORP | $13,925,000 | – | 1,250,000 | +100.0% | 0.20% | – |
ADAP | Sell | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $13,470,000 | -85.1% | 2,499,025 | -77.9% | 0.19% | -88.6% |
COGT | New | COGENT BIOSCIENCES INC | $11,518,000 | – | 1,025,641 | +100.0% | 0.16% | – |
ARYA | ARYA SCIENCES ACQUISITION CO | $10,850,000 | +0.3% | 1,000,000 | 0.0% | 0.15% | -23.2% | |
FLACU | New | FRAZIER LIFESCIENCES ACQUISITION COunit 12/09/2025 | $10,380,000 | – | 1,000,000 | +100.0% | 0.14% | – |
TXMD | New | THERAPEUTICSMD INC | $9,453,000 | – | 7,812,500 | +100.0% | 0.13% | – |
LYRA | LYRA THERAPEUTICS INC | $9,301,000 | +0.5% | 815,849 | 0.0% | 0.13% | -23.1% | |
PASG | PASSAGE BIO INC | $8,250,000 | +95.0% | 322,630 | 0.0% | 0.12% | +49.4% | |
HSAQ | HEALTH SCIENCES ACQ CORP 2 | $8,006,000 | +16.5% | 625,000 | 0.0% | 0.11% | -11.1% | |
HLXA | New | HELIX ACQUISITION CORP | $7,959,000 | – | 700,000 | +100.0% | 0.11% | – |
CRNX | Sell | CRINETICS PHARMACEUTICALS INC | $7,959,000 | -78.2% | 564,102 | -75.8% | 0.11% | -83.4% |
FVAM | New | 5 01 ACQUISITION CORP | $7,628,000 | – | 750,000 | +100.0% | 0.11% | – |
MGEN | New | MIRAGEN THERAPEUTICS INC | $7,434,000 | – | 451,932 | +100.0% | 0.10% | – |
IMRA | Sell | IMARA INC | $5,486,000 | +8.0% | 248,804 | -0.4% | 0.08% | -17.2% |
PROF | New | PROFOUND MEDICAL CORP | $3,954,000 | – | 192,311 | +100.0% | 0.06% | – |
XFOR | Sell | X4 PHARMACEUTICALS INC | $3,453,000 | -8.8% | 536,962 | -4.0% | 0.05% | -30.4% |
CEREW | New | CEREVEL THERAPEUTICS HLDNG INC*w exp 06/09/2027 | $1,318,000 | – | 233,333 | +100.0% | 0.02% | – |
OVID | OVID THERAPEUTICS INC | $658,000 | -59.8% | 285,000 | 0.0% | 0.01% | -70.0% | |
EPIX | Exit | ESSA PHARMA INC | $0 | – | -470,428 | -100.0% | -0.06% | – |
CLDX | Exit | CELLDEX THERAPEUTICS INC NEW | $0 | – | -353,072 | -100.0% | -0.10% | – |
GRTX | Exit | GALERA THERAPEUTICS INC | $0 | – | -825,118 | -100.0% | -0.14% | – |
ARYBU | Exit | ARYA SCIENCES ACQUISITION CORPunit 06/09/2027 | $0 | – | -700,000 | -100.0% | -0.14% | – |
VSTM | Exit | VERASTEM INC | $0 | – | -8,066,171 | -100.0% | -0.18% | – |
FSDC | Exit | FS DEV CORP | $0 | – | -1,000,000 | -100.0% | -0.20% | – |
PRVL | Exit | PREVAIL THERAPEUTICS INC | $0 | – | -1,915,568 | -100.0% | -0.36% | – |
RLMD | Exit | RELMADA THERAPEUTICS INC | $0 | – | -781,290 | -100.0% | -0.54% | – |
RTRX | Exit | RETROPHIN INC | $0 | – | -4,635,687 | -100.0% | -1.56% | – |
EIDX | Exit | EIDOS THERAPEUTICS INC | $0 | – | -2,163,271 | -100.0% | -2.00% | – |
MCRB | Exit | SERES THERAPEUTICS INC | $0 | – | -4,750,000 | -100.0% | -2.46% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
About RA Capital Management
RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.
The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.
RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.
Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.
Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ASCENDIS PHARMA A/S - ADR | 35 | Q3 2023 | 25.5% |
WAVE LIFE SCIENCES PTE LTD | 32 | Q3 2023 | 26.3% |
TG THERAPEUTICS INC | 30 | Q4 2021 | 6.3% |
ZOGENIX INC | 26 | Q4 2021 | 9.5% |
BIOCRYST PHARMACEUTICALS | 23 | Q1 2019 | 9.2% |
DICERNA PHARMACEUTICALS INC | 23 | Q3 2019 | 5.8% |
RHYTHM PHARMACEUTICALS INC | 22 | Q3 2023 | 4.4% |
ACHILLION PHARMACEUTICALS INC | 19 | Q4 2017 | 17.2% |
KALA PHARMACEUTICALS INC | 19 | Q1 2022 | 4.4% |
SOLID BIOSCIENCES INC | 19 | Q3 2022 | 6.8% |
View RA Capital Management's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
ARS Pharmaceuticals, Inc. | September 25, 2023 | 9,459,678 | 9.9% |
CymaBay Therapeutics, Inc. | September 22, 2023 | 6,940,000 | 6.2% |
BELLUS Health Inc.Sold out | August 14, 2023 | 0 | 0.0% |
Kinnate Biopharma Inc.Sold out | August 14, 2023 | 0 | 0.0% |
Vor Biopharma Inc. | August 11, 2023 | 22,780,343 | 33.7% |
DICE Therapeutics, Inc.Sold out | August 09, 2023 | 0 | 0.0% |
Acumen Pharmaceuticals, Inc. | July 25, 2023 | 14,981,618 | 25.9% |
Talaris Therapeutics, Inc. | July 06, 2023 | 2,333,175 | 5.5% |
Aerovate Therapeutics, Inc. | June 27, 2023 | 8,293,148 | 30.0% |
Satsuma Pharmaceuticals, Inc.Sold out | June 12, 2023 | 0 | 0.0% |
View RA Capital Management's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13D | 2024-03-28 |
3 | 2024-03-27 |
4 | 2024-03-27 |
3 | 2024-03-25 |
4 | 2024-03-25 |
SC 13G | 2024-03-25 |
SC 13G | 2024-03-25 |
SC 13D/A | 2024-03-18 |
SC 13D/A | 2024-03-11 |
4 | 2024-03-06 |
View RA Capital Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.